![]() ![]() More than 1,000 companies have been identified to be involved in developing molecular diagnostics and 268 of these are profiled in the report along with tabulation of 659 collaborations. The number of companies involved in molecular diagnostics has increased remarkably during the past few years. Currently, there has been a considerable interest in developing rapid diagnostic methods for for point-of-care and biowarfare agents such as anthrax. Molecular diagnostic technologies are also involved in development of personalized medicine based on pharmacogenetics and pharmacogenomics. ![]() Molecular diagnostics is being combined with therapeutics and forms an important component of integrated healthcare. Genetic screening tests, despite some restrictions is a promising area for future expansion of in vitro diagnostic market. Initial applications of molecular diagnostics were mostly for infections but are now increasing in the areas of genetic disorders, preimplantation screening and cancer. This includes several polymerase chain reaction (PCR)-based technologies, fluorescent in situ hybridization (FISH), peptide nucleic acids (PNA), electrochemical detection of DNA, sequencing, mitochondrial DNA, biochips, nanotechnology and proteomic technologies. This report describes and evaluates the molecular diagnostics technologies that will play an important role in practice of medicine, public health, pharmaceutical industry, forensics and biological warfare in the 21st century. 21, 2019 (GLOBE NEWSWIRE) - The "Molecular Diagnostics - Technologies, Markets and Companies" report from Jain PharmaBiotech has been added to 's offering. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |